Thiothalidomides as neuroprotectants drugs for ALS

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$238,026.00
Award Year:
2005
Program:
SBIR
Phase:
Phase I
Contract:
1R43NS050936-01A1
Award Id:
76404
Agency Tracking Number:
NS050936
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
P2D, Inc., 3130 Highland Ave, 3Rd Fl, Cincinnati, OH, 45219
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
SOMASUNDAR GABBITA
(513) 475-6618
pgabbita@p2dinc.com
Business Contact:
(513) 475-6618
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): The goal of this Phase 1 SBIR proposal is to identify lead drug candidates from a library of tumor necrosis factor a (TNF-alpha) inhibitors for treating amyotrophic lateral sclerosis (ALS). ALS is a motor neuron disorder that affects tens of thousands of Americans and current drugs display limited efficacy. An unmet need exists for new and effective treatments for ALS. Recent evidence identifies TNF-alpha as a drug target for treating ALS. TNF-a levels are elevated in ALS patient serum and spinal cord of ALS mouse models. The selective TNF-a inhibitor thalidomide improves motor performance and prolongs survival in ALS mice suggesting TNFa as an ALS drug target. Phase 2 Discovery has developed a family of proprietary thiothalidomides that are up to 30-fold more potent in inhibiting TNF-a compared to thalidomide. Thiothalidomides are predicted to be more potent than thalidomide for symptomatic improvement in ALS mice. Phase 2 Discovery will evaluate drug efficacy of thiothalidomides in ALS mice by employing a proprietary ELISA-based biomarker of neuronal damage, cleaved microtubule-associated protein tau (C-tau). Our studies indicate that spinal cord C-tau is an objective biomarker of ALS-associated motor neuron damage and drug efficacy in ALS mice. The efficiency, reliability and specificity of C-tau ELISA for quantifying ALS associated neuropathology allows drug discovery to proceed faster, use fewer animals and reduce costs compared to currently used endpoints. The proposed study will determine the efficacy of TNF-alpha inhibiting thiothalidomides employing rotorod motor performance scores and C-tau biomarker levels in ALS mice. SPECIFIC AIM: Determine the effect of thiothalidomides on rotorod motor performance, spinal cord C-tau levels and spinal cord TNF-alpha levels in ALS mice.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government